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The potential of cancer prevention
In 28 out of 40 United Nations–defined European coun-
tries, cancer is now the leading cause of premature death, 
and the second most common in the other 12, with a total 
of 1.93 million deaths and 3.91 million new incident cases 
in 2018.1 Those numbers are projected to rise to 2.55 mil-
lion deaths and 4.75 million incident cases in Europe by 
2040, as a result of population aging and growth, repre-
senting an overall increase in number of deaths by 32%.2 
Notably, however, these estimates are based on prediction 
models taking current incidence rates and time trends into 
consideration, so that preventive actions taken today could 
change this forecast, i.e., lead to lower than those expected 
numbers. The cancer cost in 27 countries in the European 
Union in 2009 was €126 billion, 60% incurred in non-
healthcare areas, with almost €43 billion in lost productiv-
ity due to early death. Of the 4 cancers studied, lung cancer 
had the highest economic burden.3
Cancer prevention has a broad scope encompassing pri-
mary, secondary, and tertiary prevention, and research in 
this domain ranges from the submicroscopic study of the 
mechanisms of carcinogenesis to the supramacroscopic 
analysis of the “causes of the causes,” also known as the 
social determinants of health.4 Recent studies from France, 
the United Kingdom, and Germany have estimated that 
around 40% of cancers in these countries could be pre-
vented.5–9 Established means of primary prevention include 
legislation and policies (e.g., on tobacco, alcohol, or hazard-
ous agents), vaccination programs (e.g., human papilloma 
virus or hepatitis B), and education about healthy lifestyles 
and behaviors (e.g., tobacco, alcohol, diet, and UV expo-
sure), as well as other risk-adapted medical prevention strat-
egies (e.g., tamoxifen or aspirin). By cancer type, a 
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proportion of 75% to 100% of all cancers of the lung, cer-
vix, esophagus, oral cavity, melanoma, and stomach in 
Europe are suggested to be preventable as a consequence of 
changes in established risk and protective factors; similarly, 
25% to 74% of all colorectal, bladder, kidney, liver, uterus, 
pancreas, and breast cancers are potentially preventable.10 
Primary prevention synergistically benefits other noncom-
municable diseases by reducing exposures to shared risk 
factors, creating healthy environments for current and future 
generations.11,12 Secondary prevention or early detection 
through organized screening programs can significantly 
reduce mortality from breast, cervical, and colorectal can-
cers, as well as incidence of cervical and colorectal can-
cers13; however, implementation of secondary prevention in 
Europe is scattered, as recently assessed.14 Tertiary preven-
tion refers to care aimed at reducing morbidity, disability, 
and risk of second primary cancer, as well as at restoring 
function and improving quality of life and participation in 
society in people diagnosed with and being treated for can-
cer. The potential to expand preventive interventions 
remains large and the evidence base for a number of meas-
ures has been summarized in the 4th edition of the European 
Code against Cancer (ECAC) (http://cancer-code-europe.
iarc.fr/index.php/en/).15 The ECAC is an integrated instru-
ment for cancer prevention that informs the general public 
how to avoid or reduce exposures to established causes of 
cancers, to adopt behaviors to reduce cancer risk, and to par-
ticipate in vaccination and screening programs under the 
appropriate national guidelines. It also acts as a guide to aid 
development of national health policies in cancer preven-
tion, as has been shown by the adoption of the ECAC pro-
posed structure in the comprehensive National Cancer Plans 
of several European countries.16
Cancer Prevention Europe
Research is required to provide new evidence-based preven-
tive interventions (including the continued search for addi-
tional causes of cancer) and to understand the factors that 
hamper their implementation within health care systems and 
in the community. In 2018, the international and multidisci-
plinary consortium Cancer Prevention Europe (CPE) was 
created to develop world-class prevention research to be 
translated into effective cancer prevention guidelines and 
policies at the national and international level.10,17 CPE is a 
consortium of leading European research institutions com-
mitted to prioritizing cancer prevention through cooperation 
between countries and programs in order to ensure a dedi-
cated research agenda with long-term vision, and sustaina-
ble funding and infrastructure for such research. CPE will 
focus on expanding preventive interventions and strength-
ening cancer prevention in Europe by increasing awareness 
of the needs, the associated required resources, and reducing 
inequalities in access to cancer prevention across Europe.18 
CPE will be broad in scope, covering a spectrum of research 
from human studies and laboratory science to policy 
research, as well as dissemination of the best evidence, qual-
ity indicators, and practices used. Assessment of the cost-
effectiveness of different interventions, in relation to costs 
of treatment, care, and productivity loss, will be a core com-
ponent of the initiative. Emphasis will also be placed on the 
evaluation of the impact of preventive interventions (pri-
mary, secondary, and tertiary) and advocacy dimensions of 
the prevention agenda. The agenda for CPE includes (1) 
research into optimizing the implementation of known pre-
ventive strategies (implementation research), (2) dissemina-
tion and research translation to inform policy and practice 
(advocacy), and (3) the identification of novel risk factors 
and targets for prevention (improvement and expansion). 
This agenda will be supported by a range of platforms, net-
works, and infrastructures and will draw together a wide 
network of partners. Training and capacity building will be 
integral to the initiative.
Cancer Mission for Europe: Now!
Europe is heavily fragmented in all aspects of cancer bur-
den. Cancer incidence varies considerably across European 
countries, partially due to differing risk factor prevalence 
and stages of implementation of primary prevention18; this 
is especially evident in the case of tobacco smoking.19 Even 
in countries at the forefront of cancer awareness, around 
40% of cancers—as shown—could be prevented; instead, 
numbers continue to rise.20 Cancer survival and mortality 
differs between European countries,21,22 as well as within 
countries across socioeconomic groups,23 even in a country 
of high social welfare such as Denmark.24 Cancer is not just 
a common cause of death but often comes with physical suf-
fering for the patient and psychological suffering for patients 
and their families, not counting the economic burden of 
€102 per citizen, as estimated in 2009 for the European 
Union.3 A Europe-wide cancer prevention mission to 
strengthen and join forces in primary and secondary preven-
tion, as well as tertiary prevention, diagnosis, and treatment, 
and palliative care, well-resourced for significant improve-
ments in all regards, is timely and urgently needed to reduce 
the growing cancer burden in Europe. CPE has been founded 
to be one of the major drivers of such a mission.
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